Companies

Astrivax Therapeutics develops a vaccine technology platform (Launch-iT) to create virus-targeted immunotherapies for virus-driven cancers.

Equaly develops a technology platform that modulates immune responses using antigen-specific cells of the innate immune system for cancer, infectious diseases, and autoimmune disease therapies.

PDCline Pharma develops off-the-shelf cancer immunotherapy targeting lung cancer and neoantigens.